Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Jason Lettmann — FY2025 total compensation $2,470,844

Jason Lettmann is Chief Executive Officer of ALX ONCOLOGY HOLDINGS INC (ALXO). The company reported total compensation of $2,470,844 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$724,500
Bonus$0
Stock awards$0
Option awards$1,447,488
Non-equity incentive plan$298,856
Pension and non-qualified deferred compensation$0
All other compensation$0
Total$2,470,844

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure ALX ONCOLOGY HOLDINGS INC filed April 20, 2026, accession 0001193125-26-163936.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025Chief Executive Officer$724,500$0$0$1,447,488$298,856$0$0$2,470,844
FY2024Chief Executive Officer$700,000$0$3,168,000$2,480,230$292,600$0$0$6,640,830

Totals as disclosed in each year's own compensation disclosure for ALX ONCOLOGY HOLDINGS INC.

04

The other named executive officers of ALX ONCOLOGY HOLDINGS INC

Named executive officerRoleFY2025 total
Jason Lettmann this pageChief Executive Officer$2,470,844
Harish ShantharamChief Financial Officer$1,700,673
Jaume PonsFormer President and Chief Scientific Officer$973,729
Shelly WongSenior Vice President, Finance and Chief Accounting Officer$940,405

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full ALX ONCOLOGY HOLDINGS INC compensation brief.

05

The company page

Jason Lettmann's compensation sits inside ALX ONCOLOGY HOLDINGS INC's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The ALX ONCOLOGY HOLDINGS INC (ALXO) compensation brief